Effect of Growth Hormone and Estrogen Replacement Therapy on Bone Mineral Density in Women with Turner Syndrome: A Meta-Analysis and Systematic Review

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 Sep 28

PMID 37765128

Authors

Weronika Szybiak

Barbara Kujawa

Milosz Miedziaszczyk

Katarzyna Lacka

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is a serious implication of Turner syndrome (TS). Common methods for the treatment of TS are growth hormone (GHT) and estrogen replacement therapy (ERT). We examined the relationship between the treatment of TS and bone mineral density (BMD) of the lumbar spine. The purpose of our study was to show the currency of BMD states among patients with TS for treatment with GHT and ERT. We searched databases for studies published from inception to April 2023. The articles were related to TS, osteoporosis, ERT, GHT, BMD and treatment patients with TS. We applied the selection criteria: lumbar spine values at L1-L4; dual-energy X-ray absorptiometry (DXA); treatment which was applied: one group of articles: ERT and two group of articles: GHT; results performed as means ± SD. In total, 79 articles were analyzed, of which 20 studies were included and 5 were considered for meta-analysis. The total number of women in the articles selected was 71. Based on the results of the meta-analysis, the effect of ERT on BMD demonstrated a significant increase in BMD (the standardized mean difference in the random model was 0.593 g/cm, 95% CI: 0.0705 to 1.116; = 0.026), which showed that treatment with estrogen particularly increases bone mass during treatment, which contributes to reducing the risk of fractures. The effect of GHT on BMD demonstrated a non-significant decrease in BMD in patients with TS. The results for growth hormone show that this therapy does not improve bone density. However, our review emphasizes the beneficial effect of supplementing growth hormone (GH) on the clinical presentation of TS.

Citing Articles

Effectiveness and safety of hormone replacement therapy in the treatment of menopausal syndrome: a meta-analysis.

Tang Y, Ma R, Zhang L, Sun X, Wang Y Am J Transl Res. 2025; 17(1):1-15.

PMID: 39959227 PMC: 11826161. DOI: 10.62347/UGLT3830.

[Reflections on the clinical diagnosis and management of Turner syndrome].

Gu W, Zhao X Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(11):1135-1140.

PMID: 39587740 PMC: 11601105. DOI: 10.7499/j.issn.1008-8830.2407176.

Bone Quality Indices Correlate with Growth Hormone Secretory Capacity in Women Affected by Weight Excess: A Cross-Sectional Study.

Gangitano E, Curreli M, Gandini O, Masi D, Spoltore M, Gnessi L J Clin Med. 2024; 13(17).

PMID: 39274277 PMC: 11395994. DOI: 10.3390/jcm13175064.

Lifelong medical challenges and immunogenetics of Turner syndrome.

Cho W Clin Exp Pediatr. 2024; 67(11):560-568.

PMID: 39091155 PMC: 11551602. DOI: 10.3345/cep.2024.00430.

References

Luo Z, Shang X, Zhang H, Wang G, Massey P, Barton S . Notch Signaling in Osteogenesis, Osteoclastogenesis, and Angiogenesis. Am J Pathol. 2019; 189(8):1495-1500. PMC: 6699068. DOI: 10.1016/j.ajpath.2019.05.005. View

Klein K, Rosenfield R, Santen R, Gawlik A, Backeljauw P, Gravholt C . Estrogen Replacement in Turner Syndrome: Literature Review and Practical Considerations. J Clin Endocrinol Metab. 2018; 103(5):1790-1803. DOI: 10.1210/jc.2017-02183. View

Bikle D, Sakata T, Leary C, Elalieh H, Ginzinger D, Rosen C . Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res. 2002; 17(9):1570-8. DOI: 10.1359/jbmr.2002.17.9.1570. View

Souza F, Collett-Solberg P . Adverse effects of growth hormone replacement therapy in children. Arq Bras Endocrinol Metabol. 2012; 55(8):559-65. DOI: 10.1590/s0004-27302011000800009. View

Ranke M, Lindberg A . Predicting growth in response to growth hormone treatment. Growth Horm IGF Res. 2008; 19(1):1-11. DOI: 10.1016/j.ghir.2008.08.001. View

Ohlsson C, Bengtsson B, Isaksson O, Andreassen T, Slootweg M . Growth hormone and bone. Endocr Rev. 1998; 19(1):55-79. DOI: 10.1210/edrv.19.1.0324. View

Hughes D, Dai A, Tiffee J, Li H, Mundy G, Boyce B . Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med. 1996; 2(10):1132-6. DOI: 10.1038/nm1096-1132. View

Garcia-Rojas M, Palma-Cordero G, Martinez-Ramirez C, de Leon-Suarez V, Valdes-Flores M, Castro-Hernandez C . Association of Polymorphisms in Estrogen Receptor Genes (1 and 2) with Osteoporosis and Fracture-Involvement of Comorbidities and Epistasis. DNA Cell Biol. 2022; 41(4):437-446. DOI: 10.1089/dna.2021.1165. View

Nakamura T, Tsuburai T, Tokinaga A, Nakajima I, Kitayama R, Imai Y . Efficacy of estrogen replacement therapy (ERT) on uterine growth and acquisition of bone mass in patients with Turner syndrome. Endocr J. 2015; 62(11):965-70. DOI: 10.1507/endocrj.EJ15-0172. View

10.

Gravholt C, Lauridsen A, Brixen K, Mosekilde L, Heickendorff L, Christiansen J . Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult turner syndrome: a cross-sectional study. J Clin Endocrinol Metab. 2002; 87(6):2798-808. DOI: 10.1210/jcem.87.6.8598. View

11.

Lopez M, Miras M, Silvano L, Perez A, Munoz L, Centeno V . Vitamin D receptor genotypes are associated with bone mass in patients with Turner syndrome. J Pediatr Endocrinol Metab. 2011; 24(5-6):307-12. DOI: 10.1515/jpem.2011.047. View

12.

Clarke B . Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008; 3 Suppl 3:S131-9. PMC: 3152283. DOI: 10.2215/CJN.04151206. View

13.

Gravholt C, Viuff M, Brun S, Stochholm K, Andersen N . Turner syndrome: mechanisms and management. Nat Rev Endocrinol. 2019; 15(10):601-614. DOI: 10.1038/s41574-019-0224-4. View

14.

Wuster C, Harle U, Rehn U, Muller C, Knauf K, Koppler D . Benefits of growth hormone treatment on bone metabolism, bone density and bone strength in growth hormone deficiency and osteoporosis. Growth Horm IGF Res. 2000; 8 Suppl A:87-94. DOI: 10.1016/s1096-6374(98)80016-6. View

15.

Kremer M, Judd J, Rifkin B, Auszmann J, Oursler M . Estrogen modulation of osteoclast lysosomal enzyme secretion. J Cell Biochem. 1995; 57(2):271-9. DOI: 10.1002/jcb.240570211. View

16.

Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P . A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet. 2004; 36(7):720-4. DOI: 10.1038/ng1379. View

17.

Chen K, Ge B, Liu X, Ma P, Lu M, Bai M . Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture. Pharmazie. 2007; 62(5):388-91. View

18.

Wassenaar M, Dekkers O, Pereira A, Wit J, Smit J, Biermasz N . Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2009; 94(10):3721-30. DOI: 10.1210/jc.2009-0425. View

19.

Lane N . Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006; 194(2 Suppl):S3-11. DOI: 10.1016/j.ajog.2005.08.047. View

20.

Ari M, Bakalov V, Hill S, Bondy C . The effects of growth hormone treatment on bone mineral density and body composition in girls with turner syndrome. J Clin Endocrinol Metab. 2006; 91(11):4302-5. DOI: 10.1210/jc.2006-1351. View